ONKOLOGIYADA DORIVOR OʻSIMLIKLAR: ANTITUMOR POTENSIAL, KLINIK DALILLAR VA DORI VOSITALARI BILAN OʻZARO TAʼSIR
Keywords:
onkologiya, dorivor oʻsimliklar, antitumor faollik, fitoterapiya, kurkumin, paklitaksel, oʻsimlik–dori oʻzaro taʼsiri, CYP3A4.Abstract
Oʻsma kasalliklari dunyo miqyosida kasallanish va oʻlim sabablari orasida yetakchi oʻrinlardan birini egallaydi. Bemorlar orasida dorivor oʻsimliklar va ulardan tayyorlangan qoʻshimchalarga qiziqish yuqori, biroq ularning samaradorligi va xavfsizligi borasidagi daliliy baza bir xil emas. Maqsad. Dorivor oʻsimliklarning antitumor potensialini, klinik dalillar darajasini va onkologik dori vositalari bilan oʻzaro taʼsir xavfini tizimli tahlil qilish. Materiallar va usullar. PubMed, Scopus, Google Scholar va Cochrane Library maʼlumotlar bazalarida nashr etilgan ilmiy manbalarning hikoyaviy (narrativ) sharhi oʻtkazildi. Natijalar. Paklitaksel, vinka alkaloidlari va kamptotesin hosilalari oʻsimlik manbasidan olingan va klinik amaliyotda isbotlangan dori vositalaridir. Kurkumin, yashil choy polifenollari va oq omela (Viscum album) preparatlari boʻyicha preklinik natijalar umidli, ammo klinik dalillar cheklangan yoki qarama-qarshi. Dalachoy (Hypericum perforatum) CYP3A4 va P-glikoprotein induktsiyasi orqali imatinib, irinotekan kabi dorilarning samaradorligini pasaytirishi mumkin. Xulosa. Dorivor oʻsimliklar onkologiyada yangi dori vositalarini topish uchun muhim manba boʻlib qolmoqda, biroq oʻsimlik qoʻshimchalarini kimyoterapiya fonida mustaqil qoʻllash xavfli boʻlishi mumkin. Bemorlarga oʻsimlik preparatlarini qabul qilishdan oldin onkolog va klinik farmakolog bilan maslahatlashish tavsiya etiladi.
References
1.Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249.
2.World Health Organization. WHO global report on traditional and complementary medicine 2019. Geneva: WHO; 2019.
3.Newman DJ, Cragg GM. Natural products as sources of new drugs over the nearly four decades from 01/1981 to 09/2019. J Nat Prod. 2020;83(3):770–803.
4.Cragg GM, Pezzuto JM. Natural products as a vital source for the discovery of cancer chemotherapeutic and chemopreventive agents. Med Princ Pract. 2016;25(Suppl 2):41–59.
5.Wani MC, Taylor HL, Wall ME, Coggon P, McPhail AT. Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc. 1971;93(9):2325–2327.
6.Moudi M, Go R, Yien CYS, Nazre M. Vinca alkaloids. Int J Prev Med. 2013;4(11):1231–1235.
7.Fridlender M, Kapulnik Y, Koltai H. Plant derived substances with anti-cancer activity: from folklore to practice. Front Plant Sci. 2015;6:799.
8.Aggarwal BB, Sung B. Pharmacological basis for the role of curcumin in chronic diseases: an age-old spice with modern targets. Trends Pharmacol Sci. 2009;30(2):85–94.
9.Gupta SC, Patchva S, Aggarwal BB. Therapeutic roles of curcumin: lessons learned from clinical trials. AAPS J. 2013;15(1):195–218.
10.Dhillon N, Aggarwal BB, Newman RA, Wolff RA, Kunnumakkara AB, Abbruzzese JL, et al. Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res. 2008;14(14):4491–4499.
11.Yang CS, Wang X, Lu G, Picinich SC. Cancer prevention by tea: animal studies, molecular mechanisms and human relevance. Nat Rev Cancer. 2009;9(6):429–439.
12.Golden EB, Lam PY, Kardosh A, Gaffney KJ, Cadenas E, Louie SG, et al. Green tea polyphenols block the anticancer effects of bortezomib and other boronic acid-based proteasome inhibitors. Blood. 2009;113(23):5927–5937.
13.Freuding M, Keinki C, Micke O, Buentzel J, Huebner J. Mistletoe in oncological treatment: a systematic review. J Cancer Res Clin Oncol. 2019;145(3):695–707.
14.Bent S. Herbal medicine in the United States: review of efficacy, safety, and regulation. J Gen Intern Med. 2008;23(6):854–859.
15.Meijerman I, Beijnen JH, Schellens JHM. Herb-drug interactions in oncology: focus on mechanisms of induction. Oncologist. 2006;11(7):742–752.
16.Ruschitzka F, Meier PJ, Turina M, Lüscher TF, Noll G. Acute heart transplant rejection due to Saint John’s wort. Lancet. 2000;355(9203):548–549.
17.Mathijssen RHJ, Verweij J, de Bruijn P, Loos WJ, Sparreboom A. Effects of St. John’s wort on irinotecan metabolism. J Natl Cancer Inst. 2002;94(16):1247–1249.
18.Frye RF, Fitzgerald SM, Lagattuta TF, Hruska MW, Egorin MJ. Effect of St John’s wort on imatinib mesylate pharmacokinetics. Clin Pharmacol Ther. 2004;76(4):323–329.
19.Block KI, Koch AC, Mead MN, Tothy PK, Newman RA, Gyllenhaal C. Impact of antioxidant supplementation on chemotherapeutic toxicity: a systematic review of the evidence from randomized controlled trials. Int J Cancer. 2008;123(6):1227–1239.
20.Zhou S, Chan E, Pan SQ, Huang M, Lee EJD. Pharmacokinetic interactions of drugs with St John’s wort. J Psychopharmacol. 2004;18(2):262–276.